Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

ctively, based on weighted average shares outstanding of 17.6 million and 17.5 million, respectively.

Cash equivalents and short-term investments were approximately $57.0 million at September 30, 2009, compared to $13.4 million at June 30, 2009. The increase reflects the receipt of a $48.8 million upfront payment from Astellas received in July 2009.

Stephen Ghiglieri, CFO, commented, "The third quarter of 2009 represents the first time we have reported quarterly revenue, which marks a milestone for NeurogesX. Our balance sheet is also strongly positioned with $57 million in cash, cash equivalents and short term investments. Consistent with our spending guidance for 2009, we are continuing our conservative focus in advance of our upcoming PDUFA date. As a result of that focus, we have been investing in commercialization activities that require long lead times, such as setting up the distribution channel, that are necessary to implement now to be ready for our targeted first half 2010 launch. Major investments, such as sales force deployment, are still being deferred pending FDA approval of Qutenza. We are also exploring strategies to further strengthen our balance sheet ahead of a potential U.S. Qutenza launch."

Development Update

NeurogesX is advancing its planning for NGX-1998 and expects to re-initiate clinical development activities in 2010.

Conference Call Details

The Company will hold its quarterly conference call today at 9:00 a.m. ET (6:00 a.m. PT) to discuss third quarter 2009 results.

To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). To access the live web cast please visit the Investor Relations section on the corporate web site at http://www.neurogesx.com.

A replay of the conference call will be available beginning November 6, 2009 at 7:30 p.m. ET (4:30 p.m. PT) and endi
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... EDMONTON , July 27, 2015 /PRNewswire/ - Quest ... pharmaceutical company developing and commercializing products for the treatment ... Quest announces that it has closed a $1,000,000 ... private placement of 16,666,667 units of the Company at ... comprised of one common share and one common share ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... today announced a new video: 3 Ways to GHS Labels . This ... and the Globally Harmonized System (GHS) by effectively labeling chemical containers. , “With ...
(Date:7/27/2015)... ... 2015 , ... BlueInGreen® announced the addition of EnviroSales of ... world’s most efficient gas dissolution technology to all of Florida, excluding the panhandle. ... and municipal markets. With offices located in Sarasota, Sebring and Melbourne Beach, the ...
(Date:7/27/2015)... YORK , July 27, 2015 Junto ... and startups share information and develop new technology solutions, ... Sachs Policy Group (SPG), a leader in health care ... will now engage in a collaborative innovation process while, ... the latest trends in public policy, health care finance ...
Breaking Biology Technology:Quest PharmaTech Closes $1,000,000 Private Placement 2Brady Releases “3 Roads to GHS Labels” Video 2BlueInGreen Brings Water Treatment Technology to Florida 2Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4
... US Oncology , the nation,s foremost ... Oncology Clinical Development (USOCD), a full service ... the services that US Oncology Research ... a decade US Oncology Research has offered pharmaceutical and biotechnology ...
... Chimerix, Inc., a biotechnology company developing orally available ... joined the Medicines for Malaria Venture (MMV) and ... and facilitate the delivery of new, effective and ... chemical library to identify activity against malaria, and ...
... Find a Faster, More Accurate and Repeatable ... ChemImage, ( www.chemimage.com ) today announces a ... ( www.nextbreath.net ), a leading Contract Research ... Chemical Imaging for bioequivalence applications for nasal ...
Cached Biology Technology:US Oncology Provides Full Service Management of Clinical Trials 2US Oncology Provides Full Service Management of Clinical Trials 3Chimerix Joins International Network of Organizations to Cure Malaria 2Chimerix Joins International Network of Organizations to Cure Malaria 3ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions 2ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions 3
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2
... of genetically engineered foods to cause allergic reactions in ... crops. Although protocols are in place to ask questions ... that offers definitive answers. , But all of that ... developed the first animal model to test whether genetically ...
... isolation and enrichment of cells, a critical first step ... diseased or damaged tissues and organs, was found to ... for cell separation. , These findings were presented today ... meeting in Berlin, Germany. The Pall Corporation (NYSE: ...
... New research shows that pre-historic horses in Alaska may have ... change as previously thought. , The discovery by Andrew Solow ... Royal Botanic Garden, Kew and Karen Robbirt of the University ... of the National Academy of Sciences (PNAS). , The accepted ...
Cached Biology News:Tests may help answer questions about GMOs and allergies 2New technology enables faster, more efficient cell harvest: Cell therapy meeting study 2
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... album Description: Proteinase K is ... a wide range of applications purified from the ... following the carboxyl group of N-substituted hydrophobic aliphatic ... classified as a serine protease. Proteinase K is ...
...
... is a 27kDa periplasmic enzyme from E. ... to cyclic nucleotide monophosphate (NMP) intermediates. Slower ... intermediates to 3-NMPs (1). RNase ONE Ribonuclease ... that can cleave a phosophodiester bond between ...
Biology Products: